|
| Figure 3: Significantly longer time to occurrence of category C events over time in patients receiving Maraviroc (MVC) vs placebo (PBO), both plus optimized background therapy (OBT), in the MOTIVATE 1 & 2 clinical trials (combined analysis). Cox proportional hazard regression model using the following variables: baseline HIV-1 RNA, time-dependent CD4+ cell count values, age, gender, and treatment group (MVC arms vs PBO). |
